Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders elected Lawrence Klein and Chris Martin as Class II directors through the 2029 annual meeting.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected Lawrence Klein and Chris Martin as Class II directors through the 2029 annual meeting
- Director elections received 43.9 million votes each, with 1.27 million broker non-votes
- PwC ratified as independent auditor for fiscal 2026, with 45.2 million votes supporting
- Executive compensation approved on a non-binding advisory basis, with 43.0 million votes for and 875,114 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.